Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients With Advanced Melanoma

Next Previous
Trial Profile

A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients With Advanced Melanoma

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-006
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 22 Jun 2023 Results assessing efficacy of 7-year follow-up published in the Journal of Clinical Oncology.
    • 25 Oct 2021 Results of post hoc analysis of KEYNOTE-006 evaluating outcomes with ipilimumab or BRAFi , MEKi as first subsequent systemic therapy after pembrolizumab and includes patients who completed or discontinued pembrolizumab published in the Annals of Oncology
    • 24 Sep 2021 Results of post-hoc analysis of two studies (KEYNOTE-001 and KEYNOTE-006) assessing long-term outcomes for patients with early SD, partial response (PR) or complete response (CR) with pembrolizumab, published in the European Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top